Printer Friendly

CEPHALON NAMES VICE PRESIDENT OF DRUG DEVELOPMENT

 CEPHALON NAMES VICE PRESIDENT OF DRUG DEVELOPMENT
 WEST CHESTER, Pa., Dec. 16 /PRNewswire/ -- Cephalon, Inc.


(NASDAQ: CEPH) announced today the promotion of Dr. Peter Grebow to vice president, drug development, from the position of director of drug development. The announcement was made today by Dr. Frank Baldino, president and CEO of Cephalon, Inc.
 "Dr. Grebow has demonstrated his team can move lead compounds from the discovery stage through preclinical testing," said Baldino. "He has been key in positioning Cephalon to file an Investigational New Drug application with FDA in the second quarter of 1992 for the use of Myotrophin (IFG-1) to treat amyotrophic lateral sclerosis."
 Grebow joined Cephalon in early 1991 from Rhone-Poulenc Rorer, where he was vice president of drug development for Rorer Central Research, a division of Rorer Pharmaceutical Corporation. Prior to that he was director of drug disposition for Revlon Health Care Group and then for Rorer Central Research following its acquisition of Revlon.
 Cephalon plans to file their first IND in the second quarter of 1992 for Myotrophin(R) (recombinant IGF-1 (Insulin-like Growth Factor)). Myotrophin is a protein made in very small amounts in humans. Research at Cephalon has shown that IGF-1 acts as a trophic factor, stimulating the growth and prolonging the life of motor neurons which are degenerating in patients with ALS.
 Cephalon, Inc. was founded in 1987 to discover, develop and commercialize novel therapeutic products for the treatment of stroke and neurodegenerative disorders.
 -0- 12/16/91
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER


KD-JT -- NY003 -- 2677 12/16/91 08:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1991
Words:269
Previous Article:HOLLAND AMERICA WESTOURS OFFERS 'HEARTLAND' CRUISETOUR FEATURING A LOOK AT THE ALASKA AGRICULTURAL SCENE
Next Article:LASERSCOPE REJECTS ALLEGATIONS OF PATENT INFRINGEMENT
Topics:


Related Articles
CEPHALON NAMES DIRECTOR OF BUSINESS DEVELOPMENT
CEPHALON APPOINTS DIRECTOR OF MEDICAL AFFAIRS
CEPHALON CO-FOUNDER TO JOIN SYMPHONY PHARMACEUTICALS
CEPHALON APPOINTS VICE PRESIDENT, WORLDWIDE CLINICAL RESEARCH
CEPHALON APPOINTS JOSEPH DAY SENIOR VICE PRESIDENT, WORLDWIDE CORPORATE DEVELOPMENT
CEPHALON APPOINTS MONROE KLEIN VICE PRESIDENT, WORLDWIDE REGULATORY AFFAIRS
CEPHALON EXPANDS DRUG DEVELOPMENT GROUP
CEPHALON APPOINTS GRANEY VICE PRESIDENT, CLINICAL OPERATIONS
CEPHALON APPOINTS COLIN MARKLAND MEDICAL DIRECTOR, EUROPE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters